Arixa Pharmaceuticals
Palo Alto
About Arixa Pharmaceuticals
Arixa Pharmaceuticals is developing oral antibiotics for resistant Gram-negative infections, an urgent need. Their lead program is an oral prodrug of Avibactam, a broad spectrum beta-lactamase inhibitor recently approved by FDA. They have addressed and solved the medicinal chemistry issues which complicate the prodrugging of this class of compounds, and expect to receive broad composition of matter patent protection.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $13.0M
- Funding stage: M&A
- Last round: Seed (May 2018)
- Website: arixapharma.com
- Phone: [email protected]
Industries & Categories
Emergency Medicine, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/arixa-pharmaceuticals-153266 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.